期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Long lasting response to second-line everolimus in kidney cancer 被引量:6
1
作者 Antonella Virtuoso Tania Policastro +4 位作者 Michela Izzo Piera Federico Carlo Buonerba Pasquale Rescigno Giuseppe Di Lorenzo 《World Journal of Clinical Cases》 SCIE 2013年第5期166-168,共3页
In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survi... In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival(PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus. 展开更多
关键词 METASTATIC RENAL cell carcinoma Everolimus(RAD001) SUNITINIB Progression-free survival
下载PDF
Activity and safety of pegylated liposomal doxorubicin,5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma:A phase Ⅱ study 被引量:1
2
作者 Giuseppe Di Lorenzo Antonio Rea +8 位作者 Chiara Carlomagno Stefano Pepe Giovannella Palmieri Roberto Labianca Antonio Chirianni Alfonso De Stefano Vincenzo Esposito Sabino De Placido Vincenzo Montesarchio 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第48期6553-6557,共5页
AIM: To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase Ⅱ study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). M... AIM: To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase Ⅱ study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). METHODS: Thirty-one patients with hystologically- confirmed, inoperable HCC, received combination chemotherapy with PLD 25 mg/mq on d 1, 5FU 1200 mg/mq in 48 h continuous infusion, and oral FA 30 mg on d 1 and 2 every 3 wk until disease progression or intolerable toxicity. RESULTS: The median age was 65 years (range 41-82) and 28 patients were hepatitis C virus seropositive (90%). The majority of patients were Child-Pugh Class B (55%). Two patients showed a partial response (PR), and 16 had stable disease (SD). With a median follow-up of 14 mo, the median time to progression of all evaluable patients was 4 mo (95% CI 1.7-7). Median overall survival was 9 mo (95% CI 3-24 mo). After 1 year, 9 of 18 PR/SD patients were alive. Chemotherapy was well tolerated. CONCLUSION: PLD/FU/FA combination seems capable of achieving durable stabilization of HCC. The manageable toxicity supports a role for combination with other anticancer agents. 展开更多
关键词 Pegylated liposomal doxorubicin 5-FLUOROURACIL Folinic acid Hepatocellular carcinoma
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部